文献速递眼底病与葡萄膜炎

玻璃体腔注射齐夫-阿柏西普治疗非年龄相关性黄斑变性所致脉络膜新生血管

Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
PubMed 文献 · Br J Ophthalmol · 2017-01-24

这项回顾性研究纳入23眼非年龄相关性黄斑变性(AMD)相关脉络膜新生血管(CNV),接受玻璃体腔注射齐夫-阿柏西普(IVZ)1.25 mg/0.05 mL按需治疗。平均随访4±1.9个月,最佳矫正视力(BCVA)从0.67 LogMAR改善至0.58 LogMAR(p=0.0507),黄斑中心厚度(CMT)平均改善22 vs 174.5 μm(p=0.037),未观察到眼部和全身不良事件。结论认为IVZ可改善CMT,但BCVA改善有限。

要点

  • 23眼非AMD相关CNV接受IVZ 1.25 mg/0.05 mL按需治疗,平均随访4±1.9个月。
  • BCVA从0.67 LogMAR改善至0.58 LogMAR(p=0.0507),39%眼视力提升至少0.1 LogMAR。
  • CMT平均改善22 vs 174.5 μm(p=0.037),未观察到眼部和全身不良事件。

核心结论

  • IVZ可改善非AMD相关CNV患者的CMT,但BCVA改善有限。

研究设计与样本

  • 回顾性研究,纳入23眼(19例患者)非AMD相关CNV,接受IVZ 1.25 mg/0.05 mL按需治疗。

主要发现

  • CNV病因包括高度近视9眼、黄斑毛细血管扩张4眼、中心性浆液性脉络膜视网膜病变3眼、脉络膜骨瘤2眼、脉络膜炎2眼、Best病2眼、特发性1眼。
  • 平均随访4±1.9个月,IVZ注射次数中位数1次(范围1-3),末次访视时无治疗间隔中位数3个月(范围1-8)。
  • BCVA从0.67 LogMAR改善至0.58 LogMAR(p=0.0507);9/23眼(39%)BCVA提升至少0.1 LogMAR,11眼(48%)稳定(基线±0.1 LogMAR内),3眼(13%)下降至少0.1 LogMAR。
  • CMT从基线至末次访视平均改善22 vs 174.5 μm(p=0.037)。
  • 未观察到眼部和全身不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections. METHODS: This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events. RESULTS: 23 eyes of 19 patients with CNV due to high myopia (9), macular telangiectasia (4), central serous chorioretinopathy (3), choroidal osteoma (2), choroiditis (2), Best's disease (2) and idiopathic (1) were treated. The mean follow-up period was 4±1.9 months. The median number of IVZ injections was 1 (range, 1-3) and the median treatment-free interval at the time of the final visit was 3 months (range, 1-8). The mean BCVA improved from 0.67 LogMAR to 0.58 LogMAR (p=0.0507). Nine of 23 (39%) eyes had BCVA gains of at least 0.1 LogMAR, 11 (48%) eyes had stable BCVA (within 0.1 LogMAR of baseline) and 3 (13%) eyes had a BCVA decline of at least 0.1 LogMAR at the final visit. The mean CMT improved significantly from baseline until the final visit (22 vs 174.5 μm; p=0.037). No ocular or systemic adverse events were noted. CONCLUSIONS: IVZ improves CMT in patients with CNV associated with causes other than AMD, but improvements in BCVA are modest.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Braimah IZ, Stewart M, Videkar C, et al. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Br J Ophthalmol. 2017. PMID: 28119292. doi:10.1136/bjophthalmol-2016-309994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。